Van ECK Associates Corp cut its stake in Danaher Corporation (NYSE:DHR – Free Report) by 0.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,625,814 shares of the conglomerate’s stock after selling 3,382 shares during the quarter. Van ECK Associates Corp owned approximately 0.23% of Danaher worth $309,685,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Danaher during the second quarter worth approximately $10,492,520,000. State Street Corp grew its holdings in Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after buying an additional 472,608 shares in the last quarter. Capital International Investors lifted its holdings in shares of Danaher by 8.9% during the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after buying an additional 1,487,768 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Danaher by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after acquiring an additional 1,334,221 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. Evercore restated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Stifel Nicolaus cut their price target on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Finally, Guggenheim dropped their price target on Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $228.91.
Danaher Price Performance
DHR stock opened at $216.41 on Friday. The stock has a market cap of $152.13 billion, a price-to-earnings ratio of 38.44, a P/E/G ratio of 2.69 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a 50 day simple moving average of $199.46 and a 200 day simple moving average of $192.52. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the business posted $0.77 earnings per share. Research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Further Reading
- Five stocks we like better than Danaher
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
